PharmaGossipAtLast

  • Subscribe to our RSS feed.
  • Twitter
  • StumbleUpon
  • Reddit
  • Facebook
  • Digg

Monday, August 26, 2013

Press Conference Wednesday: In Wake of Controversy Over Unethical NIH-Funded Premature Baby Trial, HHS Seeks Way Forward

Posted on 12:13 PM by Unknown

Family of a Baby Enrolled in the Trial to Attend; Outcome of Aug. 28 HHS Public Meeting Could Weaken Rules for Protecting Human Research Subjects

August 26, 2013

Contact: Angela Bradbery (202) 588-7741; Sam Jewler (202) 588-7779

What: Press conference to highlight the need for the U.S. Department of Health and Human Services (HHS) to strengthen the ethical standards by which human experiments are conducted and halt any ongoing trials in which parents were not properly informed of the risks to their babies or of the purpose and nature of the research.

Publicity in April over an unethical trial conducted on premature infants, called the SUPPORT study, sparked the convening of an unusual, daylong Aug. 28 public forum at (HHS). Public Citizen’s press conference will be held during the lunch break; speakers will include parents of a baby enrolled in that controversial trial, now a six-year-old who suffers from serious health problems. At the forum, Dr. Michael Carome and Dr. Sidney Wolfe, director and founder/senior adviser of Public Citizen’s Health Research Group respectively, will be the first two witnesses to testify when it starts at 9 a.m.

In the SUPPORT study, funded by the National Institutes of Health (NIH) and conducted from 2005-2009, premature infants were exposed to an increased risk of blindness, brain injury and death. In contrast to usual clinical care, the extremely premature infants enrolled in the SUPPORT study were randomly put in two groups that each received a different experimental target range of oxygen saturation. None of the consent forms signed by parents mentioned the risk of death, and only two out of 22 noted the risk of eye damage.

Since Public Citizen publicized that study, a controversy has raged in the scientific community over what kind of consent is needed in certain kinds of clinical trials. The debate goes to the heart of how research is conducted in the U.S. and could have far-reaching, negative implications if changes are made to weaken the ethical and regulatory standards by which trials are run.

Last week, Public Citizen publicized another, similar, NIH-funded trial that has just started and that also poses known risks to premature babies without fully informing the parents about those risks or the purpose and nature of the research. It is designed to determine which of two strategies for treating anemia with blood transfusions is more likely to result in death or neurologic injury in extremely premature infants who develop anemia.

Wednesday’s meeting will be livestreamed at www.HHS.gov/live.

When: Press conference: Noon (estimated time of lunch break) EDT, Wednesday, Aug. 28
Meeting runs 9 a.m. - 5 p.m.

Who: Dr. Michael Carome, director, Public Citizen’s Health Research Group
Dr. Sidney Wolfe, founder and senior adviser, Public Citizen’s Health Research Group
Carrie Pratt and Shawn Pratt, with their six-year-old daughter Dagen Pratt, who as a baby was experimented upon in the SUPPORT study
Alice Dreger, Ph.D., professor of clinical medical humanities and bioethics at the Feinberg School of Medicine at Northwestern University
George J. Annas, JD, MPH, the William Fairfield Warren Distinguished Professor and Chair in the Department of Health Law, Bioethics & Human Rights at the Boston University School of Public Health; professor at the Boston University School of Medicine and School of Law

Where: Press conference will be held outside the front of the HHS building, 200 Independence Ave SW, Washington, D.C.
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Posted in | No comments
Newer Post Older Post Home

0 comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Popular Posts

  • Beautiful Barcelona! - Gedeon Richter ruled in breach of ABPI code
    LYNNE TAYLOR Gedeon Richter (UK) has breached the Association of the British Pharmaceutical Industry (ABPI) Code of Practice, and has brough...
  • GlaxoChinaGate contd. - Bwaaa!
    China Drug Probe 'Unfair,' Euro Group Says Thu, 09/05/2013 - 8:30am Foreign companies believe they are unfairly being singled out fo...
  • Another day, another J&J recall ... Mold found in schizophrenia drug forces Johnson & Johnson recall
    By  Bloomberg News  on September 11, 2013 at 5:25 PM, updated  September 11, 2013 at 5:27 PM Johnson & Johnson has recalled 5,000 vials ...
  • AllTrials Update
    Dear Friends Support for AllTrials around the world is growing and we need to keep it that way as we reach some crucial debates. The Europea...
  • Hurrah!
    Press Release 11 September 2013 FOR IMMEDIATE RELEASE The HRA is now implementing its plans for ensuri...
  • Advertisement
    The book addresses, in great, evidence-based detail, a general system failure caused by widespread crime, corruption, bribery and impotent d...
  • Of pigs and penicillin
    Extended Withdrawal Needed to Avoid Penicillin G Residues News US - A minimum 51-day withdrawal is necessary if penicillin G is used in pigs...
  • The Lancet has formally retracted the Jikei Heart Study paper, originally published in 2007
    . The retraction had been widely anticipated for more than a month, after a series of news reports in Japan made it clear that the long-simm...
  • Wrigley holds off on caffeinated gum as FDA reviews caffeine
    By Melissa Healy 7:54 p.m. EDT, May 9, 2013 Less than a week after the Food and Drug Administration announced that it would investigate the ...
  • Petition by Professor David Healy - please sign if you agree
    Let us see Drug Data! Drug hazards are not “trade secrets”! Drug companies maximize the sales of new drugs by hyping their benefits while do...

Categories

  • Abbott (1)
  • alltrials (1)
  • alosetron (1)
  • AstraZeneca (1)
  • Baxter (1)
  • big pharma (2)
  • bribery (7)
  • Champix (1)
  • chantix (1)
  • china (7)
  • Clinical Trails (1)
  • Clinical Trial (1)
  • corruption (5)
  • Dan Markingson (1)
  • Dan Markingson Death (1)
  • diabetes (2)
  • Diovan (1)
  • EFPIA (1)
  • glaxo (11)
  • Glaxo China bribery corruption (1)
  • gsk (7)
  • hongbao (1)
  • insurance (1)
  • Januvia (1)
  • johnson and johnson (1)
  • Lotronex (1)
  • Mefloquine (1)
  • Mental Health (1)
  • Merck (2)
  • Novartis (1)
  • pancreas (1)
  • pfizer (1)
  • pharma (1)
  • pharmaceuticals (1)
  • PhRMA (1)
  • quetiapine (1)
  • Sanofi (2)
  • scandal (1)
  • seroquel (1)
  • side effects (1)
  • suvorexant (1)
  • ucb (1)
  • Valsartan (1)
  • Zaltrap (1)

Blog Archive

  • ▼  2013 (300)
    • ►  September (40)
    • ▼  August (70)
      • Europe's drug bills piling up for Chicago pharmas
      • China probes of Glaxo, Sanofi, others put big chil...
      • Hundreds of Fosamax lawsuits vs. Merck ordered rea...
      • How much Tylenol is too much?
      • Pill Pop Culture - Big Pharma might sue over Tee S...
      • Health experts critical of pharma industry's new t...
      • Idaho gets $28 million in drug price case
      • GlaxoChinaGate contd. - Behind the China Bribery S...
      • I thought this was a joke
      • The Sunshine Act Makes for Gloomy Sales Reps
      • GlaxoChinaGate contd. - British investigator 'admi...
      • Institutional Corruption and Pharmaceutical Policy
      • Why Drug Companies Don't Care What You Think About...
      • Press Conference Wednesday: In Wake of Controversy...
      • Danny defends the indefensible
      • Amgen Said to Be Near Deal to Buy Onyx BY MICHAEL ...
      • Healthcare group Fresenius warned over Puerto Rico...
      • GlaxoChinaGate contd. - Now Lilly join the party!
      • HipOpGate - J&J Said to Weigh $3 Billion Settlemen...
      • GlaxoChinaGate contd. Briton held in China arrest...
      • Merck needs to cut costs, says analyst
      • UK gives prescribing powers to physios/podiatrists
      • Corporate Whistleblower Center Urges Drug Industry...
      • First, Do No Harm: Financial Conflicts in Medicin...
      • GlaxoChinaGate contd. - All aboard the Botox gravy...
      • Physicians under the Influence: Social Psychology ...
      • GlaxoChinaGate contd. - GSK graft probe in China m...
      • Having a BBQ this weekend? What's in your steak?
      • An interview with Ray Moynihan
      • China to Launch Fresh Probe of Drug-industry Bribery
      • How to Cover Up Research Abuse and Intimidate Crit...
      • Don't pull
      • FDA Knew of Poor Drug Production Practices at Spec...
      • Li Li Gate contd. - Novartis Says Employee Allegin...
      • GlaxoChinaGate cont. - now the overcharging issues...
      • Desert Storm veteran claims boss called PTSD suffe...
      • ChinaGate latest. Novartis Saleswoman claims she w...
      • GlaxoChinaGate contd. - BBC reports on China drug ...
      • Purdue Pharma has privately identified about 1,800...
      • At Last! - U.S. Probes Use of Antipsychotic Drugs ...
      • So Big Pharma, how's your reputation management go...
      • Novartis Hit by Scandal Over Japanese Drug Studies...
      • INTERVIEW WITH BEN GOLDACRE by Tania Ahsan
      • Bringing home the Bacon: China probe into alleged ...
      • The AllTrials campaign calls for all past and pres...
      • Which Big Pharmas are taking an offshore tax vacat...
      • GlaxoChinaGate contd. - New Whistle-Blower Alleges...
      • GlaxoChinaGate contd. - An interview with Liu Xuebin
      • China fines six companies for price fixing: Xinhua
      • Medical Malpractice Payments Fell to Lowest Level ...
      • J&J's Nucynta probe expands scrutiny of industry m...
      • Patients suffer from drug industry’s chronic greed...
      • Abbott agrees to pay $12 million fine in China bab...
      • AllTrials - what's the latest?
      • Australian pharma fury at 492 drug price cuts - Ph...
      • GlaxoChinaGate contd. - The Real Implications of t...
      • J&J slapped with HHS subpoena on Nucynta marketing
      • GlaxoChinaGate contd. the cartoon
      • Come together and boycott J&J
      • Big Pharma’s placebo problem Rebranding drugs is a...
      • For Some Men, Propecia's Sexual Side Effects May B...
      • Psychiatrists: the drug pushers - by Will Self
      • GlaxoChinaGate contd. - Will Big Pharma have to dr...
      • GlaxoChinaGate contd. - GSK scandal dangles prospe...
      • Patients Should Beware When New Drug for Overactiv...
      • China nixes patent for Gilead HIV, hepatitis drug ...
      • India pulls GSK's Tykerb patent - by Kevin Grogan
      • GlaxoChinaGate contd. - Now French, US drugs drug ...
      • Now J&J must pay for price fixing in China
      • The Curious Case Of AstraZeneca v. ACE
    • ►  July (104)
    • ►  June (81)
    • ►  May (5)
Powered by Blogger.